CTCs
TellBio Raises $5M in Series A Round, Inks Deals With Genetron, ARUP for Liquid Biopsy Platform
The startup's strategic agreements with Genetron Holdings and ARUP Laboratories will accelerate global deployment of its TellDx liquid biopsy platform.
The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.
Biocept Q4 Revenues Spike as COVID-19 Testing Continues to Soar, Core Cancer Tests Lag
The firm's fourth quarter revenues included $18.3 million in commercial test revenue, of which $17.6 million was attributable to COVID-19 tests.
Lucence, Waseda University Partner to Develop Laser-Based Liquid Biopsy Platform
The partners believe the platform, which captures high resolution images of CTCs and clusters, has potential applications in early cancer detection and disease monitoring.
CellMax Life, Sebela Pharmaceuticals Sign Commercial Agreement for Colorectal Cancer Dx Test
CellMax also completed a Series C financing round to speed up development of itsFirstSight liquid biopsy test to detect colorectal cancer and precancer polyps.